REPL

Replimune Group (REPL)

About Replimune Group (REPL)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Details

Daily high

$11.72

Daily low

$11.31

Price at open

$11.41

52 Week High

$17.00

52 Week Low

$4.92

Market cap

885.7M

Dividend yield

0.00%

Volume

149,199

Avg. volume

650,589

P/E ratio

-3.66

Replimune Group News